News & Updates

Awareness is key to preventing lipohypertrophy in diabetic patients on insulin

03 Aug 2023 by

A study on adult patients with type 2 diabetes mellitus (T2DM) treated with insulin for at least 6 months showed 2-in-5 patients had lipohypertrophy.

Awareness is key to preventing lipohypertrophy in diabetic patients on insulin

03 Aug 2023

Prevent heat-related illnesses with proactive steps

03 Aug 2023 by

The start of the Southwest Monsoon has caused the temperature to rise to above 30^◦C resulting in heat-related illnesses.

Prevent heat-related illnesses with proactive steps

03 Aug 2023

Maternal violence exposure increases children's risk of being overweight

02 Aug 2023

Children whose mothers experienced violence during pregnancy are at higher risk of developing overweight from birth to middle childhood, suggests a recent study, underscoring intergenerational transmission of social adversity in children's health.

Maternal violence exposure increases children's risk of being overweight

02 Aug 2023

Accelerometry reflects QoL in malignant pleural effusion

02 Aug 2023 by

Accelerometry appears to be an accurate measure of quality of life (QoL) in patients with malignant pleural effusion (MPE), as shown in a study. It is also a useful tool for examining subtle differences in patients following various treatment regimens, particularly drainage protocols in MPE.

Accelerometry reflects QoL in malignant pleural effusion

02 Aug 2023

High polygenic risk linked to earlier treatment initiation, escalation in glaucoma

02 Aug 2023

High glaucoma polygenic risk score (PRS) shows a significant association with earlier initiation or escalation of intraocular pressure (IOP)-lowering therapy, according to a study, noting the potential usefulness of genetic risk stratification in glaucoma.

High polygenic risk linked to earlier treatment initiation, escalation in glaucoma

02 Aug 2023

Dupilumab confers benefit in bullous pemphigoid

02 Aug 2023 by

The monoclonal antibody dupilumab, alone or in combination with conventional agents, appeared to effectively control bullous pemphigoid (BP), a study from China has shown.

Dupilumab confers benefit in bullous pemphigoid

02 Aug 2023

Original New Drug Application Approvals by US FDA (16-31 July 2023)

02 Aug 2023

New drug applications approved by US FDA as of 16-31 July 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.